PureTech Health (PRTC) Short term Debt (2021 - 2022)
PureTech Health (PRTC) reported Short term Debt of $5.2 million for Q4 2022, up 501.63% year-over-year from $857000.0 in Q4 2021, and up 501.63% on a QoQ basis from $857000.0 in Q4 2021.
PureTech Health (PRTC) has 2 years of Short term Debt data on file, last reported at $5.2 million in Q4 2022.
- Quarterly Short term Debt rose 501.63% year-over-year to $5.2 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $5.2 million (up 501.63% YoY) and the FY2022 annual result came in at $5.2 million, up 501.63% from the prior year.
- Short term Debt improved to $5.2 million in Q4 2022 per PRTC's latest filing, from $857000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $5.2 million in Q4 2022 and bottomed at $857000.0 in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 5.16 Mn |
| Dec 31, 2021 | 857,000.00 |